In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $56.26, marking a -2.46% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow lost 0.74%, while the tech-heavy Nasdaq lost 0.03%.
Shares of the company have appreciated by 11.63% over the course of the past month, outperforming the Medical sector's loss of 0.88%, and the S&P 500's gain of 2.68%.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.47 per share, which would represent year-over-year growth of 1.34%. In the meantime, our current consensus estimate forecasts the revenue to be $6.58 million, indicating a 1165.77% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$5.61 per share and revenue of $41.42 million, which would represent changes of -29.26% and +11%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.38% lower. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 147, positioning it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
